Meeting
2013 ASCO Annual Meeting
Trial of zoledronic acid and interleukin-2 to expand tumoricidal γδ T cells in vivo in patients with refractory neuroblastoma.
Authors
Joseph Gerald Pressey
University of Alabama at Birmingham, Birmingham, AL
Joseph Gerald Pressey , Julia M Adams , David R Kelly , Lawrence S Lamb Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01404702
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS10073)
DOI
10.1200/jco.2013.31.15_suppl.tps10073
Abstract #
TPS10073
Poster Bd #
41H
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.
First Author: Olivier Demaria
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2015 ASCO Annual Meeting
The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response.
First Author: Ines Esteves Domingues Pires Da Silva
Poster
2024 ASCO Genitourinary Cancers Symposium
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal